| 書目名稱 | Exploring Drug Delivery to the Peritoneum | | 編輯 | Ranjita Shegokar | | 視頻video | http://file.papertrans.cn/321/320284/320284.mp4 | | 概述 | Unique compilation of research-clinical-toxicity-regulatory data.Unique collection of DDS (drug delivery systems) explored till now.Serves one stop information source for all stages of drug targeting | | 圖書封面 |  | | 描述 | .The Peritoneal cavity (PC) is?the?key metastatic site for intra-abdominal malignancies (e.g.,?GI tract and rectal cancer). PC?sites?can be used to target several other diseases where lymphatic drug delivery is desired without dumping large?amounts?of?the?drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC),?and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy?for?cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding?of?the?role of drug delivery systems (DDS)?in?targeting drugs?in?the intraperitoneal (IP)?cavity..There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (<20 kDa) is not sufficiently long to maintain therapeutic effect. This leads to frequent or continuous dosing. Another challenge is?device-related or?catheter-related problems, such as | | 出版日期 | Book 2023 | | 關鍵詞 | peritoneal cavity; GI tract and Rectal cancer; Lymphatic Drug delivery; heated intraperitoneal chemothe | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-031-31694-4 | | isbn_softcover | 978-3-031-31696-8 | | isbn_ebook | 978-3-031-31694-4 | | copyright | Springer Nature Switzerland AG 2023 |
The information of publication is updating
|
|
|Archiver|手機版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2026-1-18 13:03
發(fā)表于 2025-3-21 18:32:17
